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Abstract
Hypoxic-ischaemic encephalopathy is a leading cause of child
death, with high mortality and morbidity, including cerebral
palsy, epilepsy and cognitive disabilities. Hypoxia-ischaemia
(HI) strongly up-regulates Signal Transducer and Activator of
Transcription 3 (STAT3) in the immature brain. Our aim was to
establish whether STAT3 up-regulation is associated with
neonatal HI-brain damage and evaluate the phosphorylated
STAT3-contribution from different cell types in eliciting dam-
age. We subjected postnatal day seven mice to unilateral
carotid artery ligation followed by 60 min hypoxia. Neuronal
STAT3-deletion reduced cell death, tissue loss, microglial and
astroglial activation in all brain regions. Astroglia-speciﬁc
STAT3-deletion also reduced cell death, tissue loss and
microglial activation, although not as strongly as the deletion in
neurons. Systemic pre-insult STAT3-blockade at tyrosine 705
(Y705) with JAK2-inhibitor WP1066 reduced microglial and
astroglial activation to a more moderate degree, but in a
pattern similar to the one produced by the cell-speciﬁc
deletions. Our results suggest that STAT3 is a crucial factor
in neonatal HI-brain damage and its removal in neurons or
astrocytes, and, to some extent, inhibition of its phosphoryla-
tion via JAK2-blockade reduces inﬂammation and tissue loss.
Overall, the protective effects of STAT3 inactivation make it a
possible target for a therapeutic strategy in neonatal HI.
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Neonatal hypoxic ischaemic encephalopathy affects 1–3 per
1000 live term births in high-income countries, with rates 5–
10 times higher in low-income settings. About 40% of
affected infants die in the neonatal period and an additional
30% have lifelong neurological deﬁcits, including cerebral
palsy, epilepsy and cognitive disabilities causing substantial
socio-economic burden to the individual, family and health-
care system (Kelen and Robertson 2010).
Signal Transducer and Activator of Transcription 3
(STAT3), a member of the STAT family, is strongly up-
regulated by hypoxia ischaemia (HI) in the immature brain
(Shrivastava et al. 2013). STAT3 activation is due to JAK2-
dependent phosphorylation of Tyr-705 (Y705), and JAK2-
independent phosphorylation of Ser-727 residues (Aggarwal
et al. 2009). Phosphorylation of both sites is associated with
post-ischaemic events (Yang et al. 2005; Heusch et al. 2011)
and phosphorylated STAT3 (pSTAT3) co-localizes with cell
death-associated DNA degradation (Wen et al. 2001). JAK2-
dependent pharmacological inhibition of pSTAT3 reduces
occlusion/reperfusion-induced damage in adult models of
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middle cerebral artery occlusion (Lei et al. 2011). The
neuroprotective effects of estradiol (Dziennis et al. 2007)
and IL6 (Jung et al. 2011) depend on inhibition of pSTAT3.
Therapeutic hypothermia also reduces pSTAT3 levels (Choi
et al. 2011).
In addition to neurons, in adult animal models of
ischaemia, activated STAT3 is also present in blood vessel
endothelia, astrocytes and microglia (Planas et al. 1996;
Justicia et al. 2000; Choi et al. 2011), potentially associating
it with neuroinﬂammation and the associated tissue repair (Yi
et al. 2007). Although some studies have looked into the
activation and up-regulation of STAT3 following neonatal
HI relating it to the balance between pro- and anti-
inﬂammatory cytokines (Shrivastava et al. 2013), the overall
function and precise role of this transcription factor in
different cell types of the neonatal injured brain remains
unclear. Using global inhibition of STAT3 phosphorylation
and brain cell type-speciﬁc deletion of the STAT3 gene, the
study reveals a critical role of neuronal and astroglial STAT3
in promoting neuronal damage and glial activation in
response to neonatal HI-insult.
Materials and methods
Animal strains and breeding strategy
The animals used in the WP1066 inhibitor experiments were from
the C57/Bl6 strain obtained from Charles River (Kent, UK). Mice
carrying ﬂoxed STAT3 allele (STAT3F/F) on SVJ129 background
(Takeda et al. 1998) were kindly provided by Prof. Shizuo Akira
from the Institute for Molecular and Cellular Biology, Osaka
University, and were initially maintained as heterozygotes
(STAT3F/wt) by crossing them with C57/Bl6 obtained from
Charles River (Kent, UK). Animals expressing cre recombinase
driven by synapsin promoter (syn::Cre, C57/Bl6 strain) were
provided by Dr Axel Behrens from the Mammalian Genetics
Laboratory, Cancer Research UK, and animals expressing cre
recombinase under the control of glial ﬁbrillary acidic protein
promoter (GFAP::Cre, FVB strain) were from Jackson Labs
(USA, http://jaxmice.jax.org/strain/004600.html, Charles River,
Kent, UK). The wild-type littermate controls in the cell type-
speciﬁc STAT3 deletion experiments were thus on mixed C57/Bl6
and SVJ129 background for the neuron-speciﬁc STAT3 deletion
or on mixed C57/Bl6 and FVB background for the astroglia-
speciﬁc deletion.
For cell type-speciﬁc STAT3 deletion studies, Syn::Cre animals
were crossed twice with STAT3F/F mice (Zhu et al. 2001; Ruff et al.
2012), to obtain homozygous CNS neuron-speciﬁc deletion of
STAT3 (STAT3ΔS). To prevent germline STAT3 deletion due to
testicular expression of the synapsin promoter (Hoesche et al. 1993;
Street et al. 2005) only female cre-positive (STAT3ΔS) and male cre-
negative STAT3F/F mice were used for breeding to generate
STAT3ΔS mutants and STAT3F/F littermate controls with Mendelian
distribution. A similar approach was used for the generation of
animals with homozygous astroglia-speciﬁc deletion of STAT3
(STAT3ΔG), by crossing GFAP::Cre mice twice with STAT3F/F
animals.
DNA isolation and genotyping
DNA extraction was performed with the ‘Wizard’ Genomic DNA
puriﬁcation system according to manufacturer’s instructions (Pro-
mega, Southampton, UK), using tail tips taken before the perfusion.
Speciﬁc oligonucleotide primers (Invitrogen, Paisley, UK) were
used for genotyping.
STAT3 ﬂox forward primer: 50-CCTGAAGACCAAGTT
CATCTGTGTGAC-30
STAT3 ﬂox reverse primer: 50-CACACAAGCCATCAAAC
TCTGGTCTCC-30
GFAP-cre forward primer: 50-ACTCCTTCATAAAGCCCT-30




All animal experiments and care protocols were carried out
according to the UK Animals (Scientiﬁc Procedures) Act 1986
and approved by the Home Ofﬁce. The ARRIVE guidelines were
followed. All experiments involved postnatal day 7 mice (P7) bred
in house.
The surgical procedures were performed as previously described
(Kendall et al. 2006). Brieﬂy, male and female postnatal day 7 (P7)
mice were anaesthetised with isoﬂuorane (5% induction, 1.5%
maintenance). The left common carotid artery was permanently
occluded with 8/0 polypropylene suture and the wound closed with
tissue glue. The mice were left to recover at 36°C and returned to the
dam for 2 h. The pups were then placed in a hypoxia chamber and
exposed to humidiﬁed 8% oxygen/92% nitrogen ( 3 L/min) at 36°C
for 60 min.
In the rodent brain at P7, some cell types are at a developmental
stage similar to a mid-third-trimester human fetus or new-born
infant, with complete cortical neuronal layering, involuted germinal
matrix, and slightly myelinated white matter (Vannucci and
Vannucci 1997).The rodent HI model at P7, though slightly
preterm, presents phenotypical similarities to the grey and white
matter injury observed in humans, i.e. tissue loss, cell-death-
mediated apoptosis, microglia-mediated immune response and
astrogliosis as well as alteration in neurobehavioural performance
(Vannucci and Vannucci 1997).
Pharmacological treatment
The JAK2 inhibitor WP1066 (Calbiochem, Watford, UK) was
dissolved in 100% dimethyl sulfoxide (DMSO) and administered
intraperitoneally at two doses of 40 mg/kg body weight (BW)
(Iwamaru et al. 2007; Horiguchi et al. 2010) 20 min prior and then
again directly after HI, as the mean half-life of WP1066 is 4.5 h
(Madden et al. 2006). The WP1066-treated animals received two
injections of 0.25 lL/g BW. The control groups received a
corresponding amount of DMSO. The animals were left to survive
for 48 h and the brains were collected for histological analysis.
Western blot analysis
For western blot analysis, the animals were sacriﬁced at 1 h following
HI. Western blot analysis was performed as previously described
(Nateri et al. 2005). For immunoblotting, we used antibody against
pSTAT3 (Y705) (New England Biolabs, Hitchin, UK).
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Tissue sample preparation
For histological assessment, the animals were sacriﬁced at 48 h
post-HI by intraperitoneal injection of pentobarbitone and perfused
with 30 mL 4% paraformaldehyde in phosphate buffered saline
(PBS). The brains were then removed, post-ﬁxed in 4%
paraformaldehyde in PBS for 1 h at 4°C, and cryoprotected for
24 h in phosphate-buffered 30% sucrose solution as described
before (M€oller et al. 1996). The brains were then frozen on dry ice,
cut on a cryostat into sequential 40-lm sections and stored at 80°C
until required.
Immunohistochemistry and histological analysis
Five cryosections from each brain (400 lm apart), obtained at 48 h
post-HI, were rehydrated in distilled water and stained using
immunohistochemistry as previously described (M€oller et al. 1996).
Brieﬂy, the sections were incubated overnight with primary
antibodies summarized in Table 1, for 2 h with biotinylated goat
anti-rabbit, -rat or -hamster (1 : 100, Vector, Peterborough, UK)
secondary antibody, followed by incubation with Avidin-Biotiny-
lated horseradish peroxidase Complex (Vector) and visualization
with diaminobenzidine/H2O2 (Fisher Scientiﬁc, Loughborough,
UK). aX immunoreactivity was enhanced with Co/Ni. Overall,
GFAP immunoreactivity was detected with the rabbit polyclonal
anti-GFAP antibody. However, for the double immunoﬂuorescence
with pSTAT3 in Fig. 1j and n we used rat monoclonal anti-GFAP
antibody, to avoid cross-staining with the rabbit polyclonal antibody
against pSTAT3 (see Table 1).
Five further cryosections from each brain with the same spacing
were stained using Terminal transferase mediated d-UTP nick end
labelling (TUNEL) (Roche, Burgess Hill, UK). The staining proce-
dure followed the manufacturer protocol with Co/Ni enhancement.
Five more sections per brain with the same spacing were stained
with cresyl violet (Nissl).
For the double immunoﬂuorescence with pSTAT3 in Fig. 1h, i, l
and m, we used Neuroﬁlament-H (h, i, l and m) as a major
component of the neuronal cytoskeleton and thus a neuronal marker,
GFAP (j and n) and aM (k and o), and followed the above-described
protocol replacing the biotinylated secondary antibodies with
ﬂuorescently labelled ones.
Infarct volume measurement
The cresyl violet-stained sections were scanned and imported into
Optimas 6.5 image analysis software (Bothell, WA, USA). The
areas of intact staining in cortex, pyriform cortex, hippocampus,
striatum, thalamus and external capsule were outlined and measured
bilaterally. The percentage tissue loss was then calculated by
converting the measured injured and uninjured areas into square
millimetres and then converting the volume by multiplying by
400 lm. The sum of these volumes was then used to calculate the
percentage of surviving brain tissue as injured/uninjured vol-
ume 9 100 (Kendall et al. 2006).
pSTAT3 immunoreactivity
To analyse the pSTAT3 immunoreactivity following HI, we counted
the number of positive cells bilaterally in three different optical
ﬁelds at 9 40 magniﬁcation in cortex and hippocampus at 0,
15 min, 1, 2, 4, 8, 16, 24, 48, 72, and 96 h following HI (n = 4
animals per group). The counts were then averaged per animal and
per group.
AlphaM score
Immunohistochemistry for aM integrin as a marker of early
microglial activation (Kloss et al. 1999; Hristova et al. 2010;
Kendall et al. 2011a; Lange et al. 2014), was performed as
previously described (Ohno et al. 1995; Kendall et al. 2006).
Semi-quantitative scores were allocated to each brain region (cortex,
pyriform cortex, hippocampus, striatum, thalamus and external
capsule) by an observer blinded to the treatment of the groups
(Table 2).
AlphaX and TUNEL
Late microglial activation and phagocytosis was assessed through
immunohistochemistry for aX integrin (Kloss et al. 1999; Hristova
et al. 2010). To analyse the aX integrin and TUNEL immunore-
activity at 48 h following HI, the number of positive cells for each
of the stains was counted bilaterally in three different optical ﬁelds
at 920 magniﬁcation in cortex, pyriform cortex, hippocampus,
striatum, thalamus and external capsule. The counts were then
averaged per animal and per group.
Table 1 List of antibodies used for immunohistochemistry
Antibody against Concentration Host species Secondary antibody Obtained from
aM integrin subunit 1 : 5000 Rat Goat anti-rat Serotec, Kidlington, UK
Cat Nr MCA711
aX integrin subunit 1 : 400 Hamster Goat anti-hamster Pierce, Paisley, UK
Cat Nr MA11C5
GFAP 1 : 6000 Rabbit polyclonal Goat anti-rabbit Dako, Ely, UK
Cat Nr Z0334
GFAP 1 : 6000 Rat monoclonal Goat anti-rabbit Zymed, Loughborough, UK
Cat Nr 13-0300
pSTAT3 (Y705) 1 : 400 Rabbit Goat anti-rabbit New England Biolabs, Hitchin,
Cat Nr 9131
Neuroﬁlament-H 1 : 10000 Chicken Goat anti-chicken Abcam, Cambridge, UK
Cat Nr ab4680
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Optical luminosity
GFAP is expressed not just by the bodies, but is also registered in the
processes of astroglial cells. In order to quantify the total intensity of
the GFAP staining in the tissue, we used optical luminosity values as
a well-established technique (M€oller et al. 1996). Images for both
ipsilateral and contralateral sides were captured with a Sony AVT-
Horn 3CCD colour video camera (24bit RGB, 760 9 570 pixel
resolution) in three different optical ﬁelds in cortex, pyriform cortex,
hippocampus, striatum, thalamus and external capsule, as well as the
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software to obtain the mean and standard deviation (SD) for optical
luminosity values (OLV). SD was subtracted from the mean for each
image and the resulting value was subtracted from the values
obtained for the surrounding glass. (M€oller et al. 1996).
Statistics
Statistical signiﬁcance was assessed through repeated testing using
Mixed Linear Model with SPSS 13.0 software (IBM Corporation,
Armonk, New York, USA), treating region as the repeated measure.
For each outcome, several regions of the brain were examined. With
repeated measures such as these, it is likely that the observations
from a single subject will be correlated, therefore the ﬁrst stage of
the analysis included the observations from all the regions tested in a
single mixed model with a random subject effect, to produce an
estimate of the treatment effect and associated inference that
accounts for the correlations in the data arising from the repeated
measures. Further post hoc Student t-tests were carried out to assess
evidence for subregional differences, p < 0.05. For each outcome,
the overall effect from the linear mixed model is reported, followed
by the results from the individual regional t-tests. All data are
presented as Mean + SEM.
Results
STAT3 phosphorylation following HI- insult in the neonatal
brain
The protein levels of pSTAT3 (Y705) were assessed through
western blot analysis. Compared to littermate controls (na€ıve,
after unilateral carotid occlusion or after hypoxia alone),
postnatal day 7 (P7) mouse pups (C57/Bl6) demonstrated
bilateral pSTAT3 (Y705) up-regulation in cortex and
hippocampus, at 1 h following a 60 min HI-insult (Fig. 1a
and b). In both regions and on both sides, the total protein
STAT3 levels in animals exposed to combined HI-injury
remained unchanged when compared to na€ıve littermate
controls (data not shown).
Similar HI-mediated pSTAT3 (Y705) increase was also
observed through immunohistochemistry. Figures 1c and d
reveal a bilateral increase in pSTAT3 (Y705) immunoreac-
tivity observed on the occluded (Fig. 1c and c.1) and non-
occluded (Fig. 1d and d.1) side, in the cortex (Figs 1c and
c.1) and hippocampus (Figs 1c,d and d.1) at 1 h following
60 min HI-insult. Carotid artery ligation alone did not result
in detectable pSTAT3 immunoreactivity (Fig. 1f).
In terms of pSTAT3 + cell density, this bilateral up-
regulation was detected in both cortex and hippocampus as
early as 1 h (Fig. 1e and g) and was still detectable at lower
levels up to 24 h following HI-insult (n = 4 animals per time
point). Cortical pSTAT3 + counts (Fig. 1e) revealed a
biphasic, bilateral increase with peaks at 1 and 4 h, and
almost no pSTAT3 + cells at 2 h post-HI. The hippocampus
(Fig. 1g) demonstrated a single-bilateral peak at 1 h with
lower variable levels in both hemispheres at later time points.
To determine the identity of the pSTAT3 + cells at 1 h
following neonatal HI insult, pSTAT3 immunoreactivity was
combined with ﬂuorescent immunostaining for neuroﬁla-
ment-H (NFH), GFAP or aM integrin subunit, and counter-
stained for nuclear 40,6-diamidino-2-phenylindole (DAPI)
ﬂuorescence in dorsoparietal cortex. As shown in Figures 1h
and i, and l and m there was clear co-localization with
neuronal NFH (red), but not with astroglial GFAP (Fig. 1j
and n) or with microglial aM (Fig. 1k and o). We did not
observe microglial and astroglial co-localization at 1h post-
HI, but such co-localization has been demonstrated at later
Table 2 Semi-quantitative scores for aM integrin
Score Microglial appearance
0 No activation
1 Focal microglial activation
2 Mild phagocytic activation affecting < 50% of the region
3 Phagocytic activation affecting > 50% of the region
4 Total phagocytic activation
Fig. 1 pSTAT3 increase in cerebral cortex and hippocampus
following HI-insult in P7 mice. (a and b) Western Blots for pSTAT3
(Y705) in cerebral cortex (a) and hippocampus (b) from na€ıve C57Bl/6
animals, animals with unilateral carotid occlusion/ischemia (Occ) or
hypoxia (Hyp) – 60 min exposure to 8% oxygen and 1 h recovery; and
animals with unilateral occlusion followed by 60 min hypoxia (HI) and
1 h recovery. Tubulin protein levels served as controls. L and R – left
and right hemispheres in na€ıve and hypoxic animals, (c) and (i) –
contralateral and ipsilateral in animals with unilateral occlusion only,
and in those with HI-insult. The strong and bilateral pSTAT3 increase
in cortex and hippocampus is only present following HI-insult (a and b).
No STAT3 activation is observed in cortex or hippocampus of na€ıve or
animals subjected to occlusion (Occ) or hypoxia alone (Hyp). (c, d and
f) HI-insult strongly increased ipsilateral (c) and contralateral (d)
pSTAT3 immunoreactivity in cortex and hippocampus (rostral part of
parietal isocortex) at 1 h post-HI. Occlusion alone (Occ) produces no
change in pSTAT3 immunoreactivity (f). (c.1 and d.1) Magniﬁed
images of the dotted boxes in cerebral cortex (c) and the CA3 region of
hippocampus (d), respectively. (e and g) Number of pSTAT3 (Y705)+
cells in ipsilateral and contralateral cerebral cortex (e) and hippocam-
pus (g) 0–96 h post-HI (Mean  SEM, n = 4 animals per group). Note
the bilateral peak at 1 and 4 h in cortex (e) and at 1-2 h in
hippocampus (g) in the animals with unilateral occlusion followed by
60 min HI compared to unilateral occlusion alone (Occ) or na€ıve
animals (t-test, ipsilateral cortex *p = 0.0063 for 1 h, p = 0.046 for 4 h;
contralateral cortex #p = 0.0015 for 1 h). (h–o) Immunoﬂuorescence
for chick polyclonal anti-neuroﬁlament-H (NFH, h, i, l, m), rat mono-
clonal anti-glial ﬁbrillary acidic protein (GFAP, j and n) and rat
monoclonal anti-aM integrin subunit (k and o) in cerebral cortex at
1 h following neonatal HI, in red, superimposed on the rabbit polyclonal
anti-pSTAT3 (Y705) ﬂuorescence in green and nuclear DAPI ﬂuores-
cence in blue. Note the co-localization of pSTAT3 and NFH (l and m,
full arrows) and the lack of such co-localization with GFAP+ astroglia
(n, empty arrows) and aM+ microglial cells (o, empty arrows),
suggesting neuronal expression of pSTAT3 at this time point post-HI.
Scale bars: c, d, f = 400 lm; c.1, d.1, h–o = 50 lm.
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time-points, i.e. 3–72 h, by other groups (Shrivastava et al.
2013; D’Angelo et al. 2015).
Neuronal deletion of pSTAT3 reduces brain damage
following HI-insult in the neonate
To explore the functional role of HI-induced STAT3
activation, animals expressing one gene copy of cre recom-
binase under the control of the synapsin promoter were
crossed twice with mice carrying 2 copies of ﬂoxed STAT3
gene (STAT3F/F), to obtain animals with homozygous CNS
neuron-speciﬁc deletion of STAT3 (STAT3ΔS) and STAT3F/F
littermate controls, on a mixed C57/Bl6xSVJ129 back-
ground.
As shown in Fig. 2a and b neuronal deletion of both copies
of the ﬂoxed STAT3 gene (STAT3ΔS) strongly reduced
western blot levels of pSTAT3 (Y705) in hippocampus and
cortex compared to STAT3F/F littermate controls at 1 h
following a 60 min HI-insult (Fig. 2a and b). However,
unlike the C57/Bl6 wild-type mice (Fig. 1a and b), the
relative pSTAT3 levels on the non-occluded, contralateral
side of the forebrain were lower, both in STAT3ΔS and in
STAT3F/F littermates.
To determine the biological impact of neuron-speciﬁc
STAT3 deletion, we next examined the effects on TUNEL+
cell death and brain volume loss, on reactive astrogliosis and
on different markers or microglial activation at 48 h
following a 60 min HI-insult. Figures 2e, g and h show that
Syn::cre-mediated deletion of STAT3 (STAT3ΔS) markedly
reduced the number of TUNEL+ cells compared to STAT3F/F
littermate controls (Fig. 2e, g and h). The TUNEL+ cells
displayed the typical pyknotic nuclear morphology (Fig. 2g-
insert, ipsilateral hippocampus STAT3F/F). The Syn::cre-
mediated reduction was observed across all six examined
forebrain regions (Mixed Linear Model, treating region as a
repeated measure, p = 0.0001): cerebral isocortex, pyriform
cortex, hippocampus, striatum, thalamus and external cap-
sule. Individually, all six regions revealed a signiﬁcant, 70–
90% decrease in the number of TUNEL+ cells in STAT3ΔS
Fig. 2 Synapsin promoter-speciﬁc deletion of STAT3 causes a
decrease in pSTAT3 (Y705) protein levels in cortex and hip-
pocampus, and reduces brain tissue loss, TUNEL+ cell death,
reactive astrogliosis and microglial activation, following neonatal
HI. (a and b) Western Blot (a) and densitometric quantiﬁcation (b) of
pSTAT3 (Y705) immunoreactivity in cerebral cortex (Ctx) and hip-
pocampus (Hip) on ipsilateral (i) and non-occluded contralateral (c)
side, 1 h after 60 min HI-insult, with tubulin control. The ratio between
pSTAT3 and tubulin immunoreactivity is shown in arbitrary units (AU)
set as 100% for ipsilateral hippocampus and cortex of STAT3F/F
control animals. Neuronal STAT3-deletion (STAT3DS) produced a
clear, bilateral reduction in pSTAT3 levels (Mean  SEM; n = 5
animals per group). (c, d and f) Ipsilateral forebrain Nissl staining
(Cresyl-Violet, at rostral parietal level) of STAT3F/F (c) and STAT3DS
(d) animals and quantiﬁcation of ipsilateral brain tissue volume loss (f)
at 48 h following HI-insult. Neuron-speciﬁc deletion of STAT3
(STAT3DS, n = 6) reduced volume loss (Mean  SEM) compared to
STAT3F/F littermates (n = 5), with signiﬁcant, individual decrease (t-
test) in cortex (p = 0.020), striatum (p = 0.008), and total volume loss
(p = 0.017). Mixed linear model, treating region as a repeated measure
revealed p = 0.024. (e, g and h) TUNEL+ staining of dying brain cells
with fragmented DNA at 48 h following HI-insult – Quantiﬁcation (e)
(number of TUNEL+ cells per 209 eye-ﬁeld, Mean  SEM) and
histochemical overview of the ipsilateral forebrain in STAT3F/F (g) and
STAT3DS (h) animals. Note the typical pyknotic nuclear morphology of
the TUNEL+ cells observed in the STAT3F/F group (g- insert,
hippocampus) and the lack of such cells in the STAT3DS group (h).
Neuron-speciﬁc deletion of STAT3 reduced TUNEL+ cell death across
all 6 examined forebrain regions, with signiﬁcant, individual decrease
(t-test) in cortex (p = 0.02), pyriform cortex (p = 0.002), hippocampus
(p = 0.001), striatum (p = 0.02), thalamus p = (0.001), external cap-
sule (p = 0.04). Mixed Linear Model, treating region as a repeated
measure revealed p = 0.0001. (i–l) GFAP immunoreactivity at 48 h –
Quantiﬁcation of the ipsilateral (i) and contralateral, non-occluded side
(j) in optical luminosity values (OLV, Mean  SEM), and low magni-
ﬁcation ipsilateral overview in STAT3F/F (k) and STAT3DS (l) animals.
The inserts in (k) and (l) show higher magniﬁcations of the dotted
regions in rostro-parietal isocortex. Note the reduced levels of GFAP
immunoreactivity in the STAT3DS animals, with signiﬁcant, individual
decrease (t-test) in ipsilateral cortex (p = 0.002) and thalamus
(p = 0.001) in (i), and in contralateral hippocampus (p = 0.018) in (j).
Mixed Linear Model, treating region as a repeated measure revealed
p = 0.001 for the ipsilateral, and p = 0.049 for the contralateral side.
(m–p) aX+ microglia at 48 h – Numbers of aX+ cells per 209 eye-ﬁeld
(Mean  SEM) on the ipsilateral (m) and contralateral, non-occluded
side (n), and their ipsilateral distribution in STAT3F/F (o) and STAT3DS
(p) animals. Note the intense staining and the round, phagocytic
morphology of the aX+ cells in the STAT3F/F animals (o-insert,
hippocampus). Neuron-speciﬁc STAT3 deletion signiﬁcantly reduced
the number of aX+cells with individual decrease (t-test) in ipsilateral
isocortex (p = 0.006), pyriform cortex (p = 0.002), hippocampus
(p = 0.010), striatum (p = 5 9 105) and thalamus (p = 0.0009) in
(m); and in contralateral pyriform cortex (p = 0.010) in (n). Mixed
Linear Model, treating region as a repeated measure revealed
p = 0.0001 for the ipsilateral and p = 0.013 for the contralateral side.
(q–s) Activation of aM+ microglia – Ipsilateral aM microglial activation
score (q, Mean  SEM) and low magniﬁcation ipsilateral overview in
STAT3F/F (r) and STAT3DS (s) animals. Note the strong microglial
activation in STAT3F/F animals with aM+ cells showing phagocytic
morphology at high magniﬁcation (r-insert, hippocampus), compared
to the STAT3DS brains exhibiting a ramiﬁed phenotype (s-insert).
Neuron-speciﬁc deletion of STAT3 reduced aM+ microglial activation
across all 6 examined forebrain regions, with signiﬁcant, individual
decrease (t-test) in isocortex (p = 1 9 105), pyriform cortex
(p = 0.002), hippocampus (p = 9 9 107), striatum (p = 1 9 107),
thalamus (p = 7 9 109), external capsule (p = 0.003). Mixed Linear
Model, treating region as a repeated measure p = 0.037. STAT3F/F
(n = 5) and STAT3DS (n = 6) in all assessments. CTX – cerebral
iscocortex, PYR – pyriform cortex, HIP – hippocampus, STR –
striatum, Thal – thalamus, EC – external capsule. *p<0.05 Scale
bars: g, h, k, l, o, p, r and s = 600 lm; inserts=30 lm; c and
d = 1200 lm.
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animals compared to their STAT3F/F littermates (p < 0.05 in
t-test).
A similar effect of the Syn::cre-mediated deletion of
STAT3 was also observed for forebrain tissue loss, i.e. the
reduction of the volume on the ipsilateral versus the non-
occluded contralateral side. Figure 2c shows large infarct in
mid-lateral isocortex (09:00-11:00 segment) and hippocam-
pus of the STAT3F/F animal (Fig. 2c) and its sparing in the
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
(m) (n) (o) (p)
(q) (r) (s)
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STAT3ΔS littermate (Fig. 2d). Quantiﬁcation of ipsilateral
volume loss (Fig. 2f) revealed strong decrease across the
different forebrain regions (Mixed Linear Model, treating
region as a repeated measure, p = 0.024), with individual
signiﬁcant decrease of 80–90% in isocortex, striatum and
total forebrain area (p < 0.05 in t-test).
In addition to cell death and brain tissue loss, Syn::cre-
mediated deletion of STAT3 also decreased HI-induced and
predominantly ipsilateral reactive astrogliosis and microglial
activation. Compared to STAT3F/F animals, their STAT3ΔS
littermates revealed less overall polyclonal GFAP-immunor-
eactivity (Fig. 2i and j), with substantially reduced and more
spotty areas of GFAP+ astroglial processes (Fig. 2k and l).
Assessment across the different forebrain regions through
Mixed Linear Model, treating region as a repeated measure
revealed a clear decrease on the ipsilateral, and milder
reduction on the contralateral side (p = 0.001 and p = 0.049,
respectively), with individual signiﬁcant decrease of 40–65%
in ipsilateral isocortex and thalamus, and of 32% in
contralateral hippocampus (p < 0.05 in t-test).
While the microglial cells in the control STAT3F/F group
48 h following a 60 min HI-insult revealed the round,
phagocytic phenotype shown in the inserts of Fig. 2o and 2r,
the microglial cells detected in the STAT3ΔS group mainly
displayed resting to activated, but still ramiﬁed morphology
(Fig. 2s-insert). Figures 2m–p show that Syn::cre-mediated
deletion of STAT3 substantially decreased microglial
immunoreactivity for aX integrin subunit, a marker of
phagocytic/late microglial activation (Kloss et al. 1999).
Quantiﬁcation of aX+ cells across the forebrain regions
through the Mixed Linear Model,treating region as a repeated
measure revealed signiﬁcant ipsilateral reduction
(p = 0.0001), with individual decreases of 50–90% in all
brain regions apart from external capsule (p < 0.05 in t-test).
Although the non-occluded, contralateral side showed much
fewer aX+ cells, Syn::cre-mediated deletion of STAT3 also
led to signiﬁcant contralateral reduction of the number of
aX+ microglia (Mixed Linear Model treating region as a
repeated measure, p = 0.013), with individual decrease of
90% in the contralateral pyriform cortex (p < 0.05 in t-test).
A similar effect was also observed for microglial activation
score (Fig. 2q) based on the aM integrin immunoreactivity
(Fig. 2r&s). Regional assessment shown in Fig. 2q revealed
a reduction in activation score in the STAT3ΔS group (Mixed
Linear Model treating region as a repeated measure,
p = 0.037), with signiﬁcant decrease of 65–90% in all six
individual ipsilateral brain regions (p < 0.05 in t-test).
Astroglial deletion of pSTAT3 reduces brain damage
following neonatal HI-insult
Compared with STAT3F/F control animals, deletion of both
STAT3 gene copies with cre recombinase driven by
astroglia-speciﬁc GFAP promoter (STAT3ΔG) signiﬁcantly
reduced the extent of TUNEL+ cell death and astrogliosis.
The effect on TUNEL+ cells is shown in Fig. 3a (Mixed
Linear Model, treating region as a repeated measure,
p = 0.02), with individual signiﬁcant decrease of 30–87%
in hippocampus, thalamus and external capsule (p < 0.05 in
t-test). However, despite the apparently consistent lower
average tissue loss values across the examined brain regions
(Fig. 3a, b and c) in STAT3ΔG animals, astroglial deletion of
STAT3 did not have a signiﬁcant effect on ipsilateral brain
tissue loss (Mixed Linear Model, treating region as a
repeated measure, p = 0.217). Likewise, microglial activa-
tion based on the aM integrin immunoreactivity (Fig. 3k)
had a trend towards reduced levels in all the examined
regions but overall was not signiﬁcantly affected
(p = 0.229).
In contrast, astroglial pSTAT3 deletion strongly reduced
HI-induced up-regulation of GFAP-immunoreactivity in both
ipsi- and contralateral brain regions (Fig. 3g,h, and i and
Fig. 3j, respectively). The extent of this reduction was
beyond that observed with STAT3ΔS (Fig. 2k and l). Analysis
with Mixed Linear Model, treating region as a repeated
measure revealed p = 0.0001 on the ipsilateral and 0.0042 on
the contralateral side, with individual signiﬁcant decrease of
50–70% in all of the six regions on the occluded and 16–65%
in four of the regions on the contralateral, non-occluded side
(p < 0.05 in t-test).
Inhibition of STAT3 Y705-phosphorylation reduces HI-
mediated glial activation
Due to the early up-regulation of pSTAT3 post-HI (Fig. 1),
the JAK2 inhibitor WP1066 was injected intraperitoneally
just before and immediately after 60 min hypoxia to prevent
STAT3 activation during the latent period. Compared to
vehicle (DMSO)-treated control animals, intraperitoneal
application of WP1066 (80 lg/g BW) signiﬁcantly reduced
the protein levels of pSTAT3 (Y705) at 1 h post-HI in both
cortex (Fig. 4a and c) and hippocampus (Fig. 4b and c) on
the ipsilateral side.
Pre- and post-insult treatment with 80 lg/g WP1066 did
not have signiﬁcant effect on ipsilateral brain tissue loss at
48 h post-HI in Mixed Linear Model, treating region as a
repeated measure (p = 0.257) (Fig. 4d–f). There was also no
signiﬁcant effect of WP1066-treatment on the number of
TUNEL+ cells (data not shown). However, reactive
astrogliosis and microglial activation on the occluded side
were affected. In the case of astroglial GFAP immunoreac-
tivity (Fig. 4g–i), analysis with Mixed Linear Model, treating
region as a repeated measure revealed p = 0.047, with
individually signiﬁcant decrease of 28% in external capsule
(p < 0.05 in t-test). Microglial activation (Fig. 4j–l) based on
aM integrin immunoreactivity was signiﬁcantly reduced in
animals treated with WP1066 (Mixed Linear Model, treating
region as a repeated measure, p = 0.041), with individually
signiﬁcant decrease of 51% in ipsilateral hippocampus
(p < 0.05 in t-test). The insert in Fig. 4d shows the typical
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Fig. 3 Astroglial deletion of STAT3 with Cre recombinase under
the control of GFAP promoter (STAT3DG) reduces cell death and
reactive astrogliosis. All graph data are shown as Mean  SEM.
(a) Ipsilateral brain tissue volume loss was not signiﬁcantly affected
despite the consistent lower average tissue loss values across the
examined brain regions in the STAT3ΔG animals. (b and c) Ipsilateral
forebrain Nissl staining (Cresyl-Violet, at rostral parietal level) of
STAT3F/F (b) and STAT3DG (c). (d) Reduction in the number of
TUNEL+ dying cells (per 209 eye-ﬁeld) at 48 h following HI, with
signiﬁcant, individual decrease (t-test) in the STAT3DG group (n = 12)
compared to STAT3F/F littermate controls (n = 15), in ipsilateral
hippocampus (p = 0.041), thalamus (p = 0.049) and external capsule
(p = 0.040). Mixed Linear Model treating region as a repeated
measure revealed p = 0.040. (e and f) Histochemical overview of
TUNEL+ cell death of the ipsilateral forebrain in STAT3F/F (e) and
STAT3DG (f) animals. Note the high density of typical pyknotic nuclear
morphology of the TUNEL+ cells observed in the STAT3F/F group (e-
insert, hippocampus) and the reduced number of such cells in the
STAT3DG group (f). (g) Strong reduction in ipsilateral reactive
astrogliosis (GFAP immunoreactivity in OLV), with signiﬁcant, individ-
ual decrease (t-test) across all 6 ipsilateral forebrain regions –
isocortex (p = 0.0006), pyriform cortex (p = 0.003), hippocampus
(p = 0.0002), striatum (p = 0.003), thalamus (p = 0.0003) and external
capsule (p = 1 9 105). Mixed Linear Model, treating region as a
repeated measure revealed p = 0.001. (h and i) Low magniﬁcation
ipsilateral overview in STAT3F/F (h) and STAT3DG (i) animals. The
insert in H shows higher magniﬁcation of the dotted region in rostro-
parietal isocortex. Note the reduced levels of GFAP immunoreactivity
in the STAT3DG animals. (j) Strong reduction in contralateral reactive
astrogliosis with signiﬁcant, individual decrease (t-test) in contralateral
isocortex (p = 0.010), hippocampus (p = 0.003), thalamus (p = 0.040)
and external capsule (p = 6 9 106). Mixed Linear Model, treating
region as a repeated measure revealed p = 0.004. (k) Ipsilateral
microglial activation score based on the aM integrin immunoreactivity
was decreased in all examined regions but overall was not signiﬁcantly
affected. STAT3F/F (n = 15) and STAT3DG (n = 12) in all assessments.
*p<0.05 Scale bars: e, f, h and i = 600 lm; inserts=30 lm; b and
c = 1200 lm.
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phenotype of strongly aM immunoreactive, phagocytic
microglia in the vehicle (DMSO) control group, compared
to ramiﬁed microglia with reduced aM immunoreactivity in
the WP1066-treated animal (Fig. 4e-insert).
Discussion
As shown in the current study, in a Rice-Vannucci model of
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STAT3 (STAT3DS) clearly reduced forebrain cell death and
tissue loss, as well as microglial and astroglial activation.
Astroglia-speciﬁc STAT3 deletion (STAT3DG) blocked reac-
tive astrogliosis and attenuated cell death, but had a more
moderate effect on tissue loss and active microgliosis. A
combined pre-insult and immediate post-insult blockade of
JAK2 with systemically applied WP1066 inhibited the HI-
induced forebrain STAT3(705)-phosphorylation and reduced
HI-brain damage based on some evidence for astroglial and
microglial post-HI response. However, this effect was weak
and did not lead to a statistically signiﬁcant reduction in brain
tissue loss. Overall, our data suggest a critical role for
STAT3, and possibly also a contribution in neonatal HI-brain
damage via Tyr705 phosphorylation.
There are signiﬁcant differences in the response of
different mouse strains to the Rice-Vannucci model of
neonatal HI (Sheldon et al. 1998; Rocha-Ferreira et al.
2015), with C57/Bl6 demonstrating an increasing degree of
injury with increasing duration of hypoxia, and SVJ129
demonstrating relative resistance to injury. As both the
cell-speciﬁc deletion strains used in our experiments were
on mixed C57/Bl6 background with either FVB (astroglial)
or SVJ129 (neuronal), and because of the reported
susceptibility of the C57/Bl6 strain to the neonatal HI
model, we chose to use the latter for the STAT3 inhibitor
experiments.
The increase of pSTAT3 (Y705) in the current study, was
speciﬁc for HI, peaking at 1–4 h following insult (Fig. 1e
and g). We did not observe STAT3 activation in the brains of
na€ıve, animals subjected to hypoxia alone or of those with
unilateral carotid occlusion alone (Fig. 1a and b), suggesting
a HI-dependent pattern of STAT3 activation (Shrivastava
et al. 2013). Interestingly, the early pSTAT3 presence at 1 h
following HI was speciﬁc for neurons but not for the GFAP+
astrocytes (Fig. 1j and n) or the aM+ microglia (Fig. 1k and
o), preceding the previously observed up-regulation from 3
to 72 h post-HI in micro- and astroglial populations (Shri-
vastava et al. 2013), and suggesting an additional, time-
dependent and cell-speciﬁc pattern of STAT3 activation. The
pSTAT3-localization around neuronal cell body-near pro-
cesses (Fig. 1h and i and l and m) could be explained with a
previously described role for this retrogradely transported
axonal molecule in injury-induced axonogenesis of hip-
pocampal neurons (Ohara et al. 2011).
Total STAT3 protein levels remained unaffected and
similar to the expression observed in na€ıve animals (data not
shown), implying that the functional effect of STAT3 is
probably elicited by some post-translational modiﬁcation
and/or translocation, cytoplasmic translation and nuclear
transcription (Nicolas et al. 2012; Haghikia et al. 2014).
Most of the immediate/early HI damage in the Rice-
Vannucci model occurs on the occluded side (obvious from
Nissl histology in Fig. 2c and d or phagocytic, aX+
microglia in Fig. 2m–p). However, pSTAT3-activation is
bilateral (Figs 1a and b and 2a and b) with contralateral
intensity possibly depending on the strain background. This
bilateral activation suggests that STAT3 is not a directly
pathogenic effector molecule but rather exerts a permissive,
but nevertheless substantial, predisposing role in mediating
HI-injury. Although the contralateral side in the Rice-
Vannucci model is often used as intra-animal control
reference for ipsilateral damage (Vannucci et al. 1988;
Towﬁghi et al. 1994; Skoff et al. 2007; Shrivastava et al.
2012), some studies report bilateral change in the expression
of some cytokines, for example Hypoxia Inducing Factor
alpha and P-Akt (Shrivastava et al. 2012), suggesting that
hypoxia can regulate some mediators contributing, but not
sufﬁcient to cause long-term damage. The same study reports
some degree of delayed contralateral atrophy in hippocampus
and corpus callosum (Shrivastava et al. 2012). Severe HI-
insult in the Rice-Vannucci model following unilateral
carotid occlusion and prolonged (60 + min) hypoxia is
associated not only with substantial acidosis in the territory
of the ipsilateral medial cerebral artery but also with very
pronounced contralateral pH drop (Kendall et al. 2011b),
which could contribute to the rapid STAT3 activation on the
Fig. 4 Jak2-inhibition with WP1066 reduces STAT3–phosphory-
lation (Y705), reactive astrogliosis and microglial activation
following neonatal HI. (a–c) Western Blots (a and b) of pSTAT3
(Y705) immunoreactivity in cerebral cortex (a) and hippocampus (b)
and their densitometric quantiﬁcation (c) in arbitrary units (AU) against
a tubulin control (Mean  SEM) at 1 h after 60 min HI-insult.
Intraperitoneal WP1066 injection at a combined dose of 80 lg/g BW
(20 min prior and directly after 60 min HI-insult), reduces pSTAT3
(Y705) levels in both cortex and hippocampus in the ipsi- (i) and
contralateral (c) hemisphere (n = 6), when compared to the vehicle
(DMSO) -injected littermate controls (n = 5). *Signiﬁcant effect for
WP1066 versus DMSO (unpaired t-test) for ipsilateral cortex
(p = 0.005) and ipsilateral hippocampus (p = 0.005). (d, e, g, h, j
and k) Nissl staining of whole forebrain (d and e), and ipsilateral
immunoreactivity for astroglial GFAP (g and h) and aM+ microglia at
rostro-parietal level (j and k) 48 h after HI-insult in animals injected with
vehicle (DMSO) (d, g and j) or WP1066 (e,h and k). The inserts in (g
and h) show WP1066-induced reduction in GFAP immunoreactivity in
external capsule and in (j and k) the disappearance of aM+ microglial
phagocytes in the hippocampal CA3 subregion. (f, i, and k) Quanti-
tative assessment of WP1066 effect vs DMSO (n = 9 per group) on
ipsilateral brain tissue volume loss (f), GFAP immunoreactivity in OLV
(i) and aM microglial activation score (l). All graph data are shown as
Mean  SEM. In the Mixed Linear Model, treating region as a
repeated measure did not reveal signiﬁcant effect for volume loss (f),
but demonstrated reduced astrogliosis (i, p = 0.019) and microglial
activation score (l, p = 0.049) with signiﬁcant, individual decrease (t-
test) in external capsule (GFAP-immunoreactivity, i, p = 0.040) and in
hippocampus (microglia, l, p = 0.048). Scale bars: d and e = 1200 lm,
g, h, j and k = 300 lm; inserts = 30 lm.
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non-occluded side observed in the current study. Moreover,
the elevated, contralateral levels of pSTAT3, and the fact that
neuronal as well as astroglial STAT3 deletion inhibit
contralateral astrogliosis (Figs 2j and 3d) and microgliosis
(Fig. 2n) also points to a more long-term involvement in
pathways underlying delayed contralateral atrophy (Shrivas-
tava et al. 2012).
We used 3 strategies to interfere with brain STAT3
function, i.e. removal of STAT3 gene expression in
neurons (STAT3DS), in GFAP+ astroglia (STAT3DG) and
blocking JAK2-mediated Y705-phosphorylation with
WP1066. The pharmacological inhibition produced a
relatively moderate effect. Compared to vehicle (DMSO)-
treated controls, the combined pre-HI and immediate post-
HI intraperitoneal injection of WP1066 signiﬁcantly
reduced the levels of pSTAT3 in cortex and hippocampus
(Fig. 4a–c), demonstrating that WP1066 does penetrate the
blood brain barrier at a physiologically active dose
(Hussain et al. 2007). It is possible that this reduction is
due to an incomplete, approximately 70% decrease in
Y705-phosphorylation thus permitting some residual activ-
ity, compared to complete removal in neurons or astrocytes
expressing cre recombinase. Moreover, there are several
different ways involved in STAT3 activation – phospho-
rylation at Y705 and S727, dimerization, nuclear translo-
cation, etc. (Haghikia et al. 2014) – and interference with
just one could produce a moderate result. Interestingly,
cell-speciﬁc removal of the ﬂoxed STAT3 gene, as well as
pharmacological inhibition result in partial overlap of the
histopathology phenotypes, but there are pronounced
differences in the magnitude of their impact suggesting
either direct or secondary effects.
Removal of STAT3 in astrocytes resulted in a consistent,
general decrease in reactive astrogliosis across different
regions of the ipsilateral and contralateral hemisphere,
underscoring the essential role of this transcription factor in
astroglial activation and induction of GFAP (Fukuda et al.
2007; Herrmann et al. 2008; Hong and Song 2014). Previous
studies have suggested that reactive astrogliosis is neuropro-
tective and enhances repair. Astroglial STAT3 deletion
interferes with synaptic plasticity on regenerating facial
motor neurons via astrocyte TSP1 (Tyzack et al. 2014),
delays oligodendroglial maturation in endotoxin-induced
neonatal white matter damage (Nobuta et al. 2012), and
increases inﬂammation and lesion volume, with attenuated
motor recovery in spinal cord injury (Herrmann et al. 2008).
However, in the current model, deletion of astroglial STAT3
resulting in suppression of astrogliosis was associated with
clearly reduced TUNEL+ cell death in the ipsilateral
hippocampus, thalamus and external capsule (Fig. 3d,e and
f). Although the effects were less prominent than with
neuron-speciﬁc deletion (Fig. 2e, g and h), and the decrease
in tissue loss and microglial activation did not reach the
statistical signiﬁcance needed for repeated measures, in our
study reduced astrogliosis in HI was associated with decrease
in cell death and did not increase inﬂammation or tissue loss,
thus contradicting the effects observed in other experimental
brain pathologies (Herrmann et al. 2008; Nobuta et al.
2012).
In contrast to GFAP promoter-driven deletion, pSTAT3-
deletion via the neuronal synapsin promoter produced a
general decrease of cell death across all examined regions of
the ipsilateral hemisphere, and signiﬁcantly reduced tissue
loss in cerebral isocortex and striatum, and overall ipsilateral
forebrain volume loss. It also resulted in a signiﬁcant
reduction in microglial aM activation score and the number
of aX+ phagocytes. Microglia do not express synapsin
during embryonic or post-natal development (K€ugler et al.
2001). The neuronal effects on reactive astrogliosis are fairly
moderate (Fig. 2i and j), and the decrease in microgliosis in
STAT3DG animals did not reach statistical signiﬁcance
(Fig. 3k). Therefore, the observed reduction in microglial
activation in the STAT3DS animals is probably a consequence
of reduced neuronal signalling and/or the strongly decreased
cell death and tissue loss. Following neonatal HI-injury
activated microglia, similarly to other pathologies, are a
major marker of damage (Ohno et al. 1995) and source of
inﬂammatory cytokines contributing to cell death, tissue loss
and astroglial activation, as well as an important contributor
to endogenous defence mechanisms through effective elim-
ination of apoptotic neurons (Faustino et al. 2011). Acti-
vated microglial cells produce interleukin-6 (IL6)
(Lambertsen et al. 2012), a strong astroglial activator
in vitro (Benveniste et al. 1995) and in vivo (Campbell
et al. 1993; Galiano et al. 2001). Moreover, elevated levels
of microglial IL6 following neonatal HI-injury correlate with
increase in pSTAT3 + astrocytes (Shrivastava et al. 2013).
Interestingly, WP1066 strongly inhibits microglial IL6
production (Lambertsen et al. 2012), which in the current
study could contribute to the WP1066-dependent reduction
in reactive astrogliosis.
Overall, neuronal and astroglial STAT3 are clearly
involved in the pathways underlying cell death, tissue loss
and gliosis following neonatal HI but they do differ with
respect to the target of their effect. Y705-phosphorylation
does contribute to HI histopathology; however a better
understanding of this and the other pathway(s) through
which STAT3 activation is involved in HI-brain damage
would considerably improve the therapeutic potential of
interfering with STAT3 in a clinical setting.
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